GNC-035

Phase 2Small molecule

SSichuan Baili Pharmaceutical Co., Ltd.

GNC-035 is one of 126 small molecule programs targeting Non-Hodgkins Lymphoma. It is currently in Phase 2.

Indications

Total Trials

Active Trials

125

Competitors

Pipeline

Status by Indication[3][1]

Indication

Non-Hodgkins LymphomaRecruiting

Refractory Hematologic MalignancyActive, not recruiting

Breast CancerActive, not recruiting

Chronic Lymphocytic LeukemiaActive, not recruiting

Non-Hodgkins LymphomaPreclinical

Recruiting

Refractory Hematologic MalignancyPhase 1

Active, not recruiting

Breast CancerPhase 1

Active, not recruiting

Chronic Lymphocytic LeukemiaPhase 2

Active, not recruiting

Competition

Competitive Landscape

744 competitors in Breast Cancer

#DrugCompanyPhaseTrials

GNC-035

SSichuan Baili Pharmaceutical Co., Ltd.

Phase 2

1 2

Adenocard

Astellas

Preclinical

2 3

Lexiscan

Astellas

Preclinical

1 4

Methylthioninium Chloride

PProvepharm SAS

Preclinical

3 5

Sporanox

SSebela Pharmaceuticals Development LLC

Preclinical

1 6

Vfend

PPrism Pharmaceuticals

Rilvegostomig

1 8

Ablavar

LLantheus Medical Imaging

Preclinical

2 9

Naltrexone/bupropion

Novo Nordisk

Preclinical

1 10

Sertraline ODT

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

PreclinicalRecruiting

Non-Hodgkins Lymphoma

NCT06066203

Clinical

Trials by Indication[1]

Locally Advanced or Metastatic Solid Tumors1 trial

A Study of GNC-035, a Tetra-specific Antibody, in Participants With Locally Advanced or Metastatic Solid Tumors

Withdrawn·SSichuan Baili Pharmaceutical Co., Ltd.·Phase 1·NCT05039931

Refractory Hematologic Malignancy1 trial

A Study of GNC-035, a Tetra-specific Antibody, in Participants With Relapsed/Refractory Hematologic Malignancy

Active, not recruiting·SSichuan Baili Pharmaceutical Co., Ltd.·Phase 1·NCT05104775·33 enrolled

Chronic Lymphocytic Leukemia1 trial

A Study of GNC-035 in Relapsed or Refractory Chronic Lymphocytic Leukemia and Other Hematological Malignancies

Active, not recruiting·SSichuan Baili Pharmaceutical Co., Ltd.·Phase 1/2·NCT05944978·3 enrolled

Breast Cancer1 trial

A Study of GNC-035, a Tetra-specific Antibody, in Participants With Locally Advanced or Metastatic Breast Cancer

Active, not recruiting·SSichuan Baili Pharmaceutical Co., Ltd.·Phase 1·NCT05160545·36 enrolled

Non-Hodgkins Lymphoma1 trial

An Open, Multicenter, Phase I / II Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics / Pharmacodynamics and Antitumor Activity of GNC-035 Tetra-specific Antibody Injection in Relapsed or Refractory Non-Hodgkin 's Lymphoma and Other Hematological Malignancies

Recruiting·SSichuan Baili Pharmaceutical Co., Ltd.·Preclinical·NCT06066203·40 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for GNC-035. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — GNC-035 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for GNC-035. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Sichuan Baili Pharmaceutical Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: SSichuan Baili Pharmaceutical Co., Ltd.

GNC-035

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Trials by Indication[1]

Locally Advanced or Metastatic Solid Tumors1 trial

Refractory Hematologic Malignancy1 trial

Chronic Lymphocytic Leukemia1 trial

Breast Cancer1 trial

Non-Hodgkins Lymphoma1 trial

References

Drug Info

Quick Facts

Related News